BioPharma Resources

Drug Trial Radar · NCT05948475

Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma

A Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib VS Physician's Choice in Subjects With FGFR-altered, Chemotherapy- and FGFR Inhibitor-Cholangiocarcinoma

Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 200 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Dec 20, 2023

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Sponsor type
Industry
First posted
Jul 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a Phase III, Randomized, Controlled, Global Multicenter Study to Evaluate the Efficacy and Safety of Oral Tinengotinib versus Physician's Choice in Subjects with Fibroblast Growth Factor Receptor (FGFR)-altered, Chemotherapy- and FGFR Inhibitor-Refractory/Relapsed Cholangiocarcinoma

Conditions

  • Cholangiocarcinoma

Interventions

  • Tinengotinib 8 mgDrug

    Subjects randomized to receive tinengotinib will receive a starting dose of either 8 mg QD., self-administered orally QD in 28-day cycles.

  • Tinengotinib 10 mgDrug

    Subjects randomized to receive tinengotinib will receive a starting dose of either10 mg QD., self-administered orally QD in 28-day cycles.

  • Physician's ChoiceDrug

    For subjects receiving FOLFOX or FOLFIRI, the subject will receive treatment every two weeks, with two administrations per each 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Incidence, duration, and severity of adverse events (AEs)Time frame: Up to 30 days from study discontinuation
  2. Part B: PFS by BICRTime frame: From first study drug administration until the date of first documented progression assessed by BICR or date of death from any cause, whichever came first, assessed up to 24 months

Locations

87 sites in 13 countries. Site status is shown where the registry gives one.

  • UCLA Medical Center

    Santa Monica, California

  • Stanford Cancer Center

    Stanford, California

  • The University of Kansas Cancer Center

    Westwood, Los Angeles, California

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • The University of Chicago Hospitals

    Chicago, Illinois

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Henry Ford

    Detroit, Michigan

  • University of Minnesota- Masonic Cancer Center, M Health Fairview

    Minneapolis, Minnesota

  • Roswell Park Comprehensive Cancer Center

    Buffalo, New York

  • Messino Cancer Centers

    Asheville, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Tennessee Oncology- Nashville

    Nashville, Tennessee

  • Vanderbilt-Ingram Cancer Center

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Texas Oncology-Sammons Cancer Center

    Dallas, Texas

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Virginia Cancer Center

    Charlottesville, Virginia

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Ordensklinikum Linz GmbH

    Linz, Austria

  • Landesklinikum Wiener Neustadt

    Wiener Neustadt, Austria

  • Universitair Ziekenhuis Antwerpen

    Antwerp, Belgium

  • Universitair Ziekenhuis Gent

    Ghent, Belgium

  • Universitair Ziekenhuis Leuven

    Leuven, Belgium

  • Institut Sainte Catherine - Institut du Cancer Avignon Provence

    Avignon, France

  • Centre Hospitalier Régional Universitaire de Besançon

    Besançon, France

  • Hopital Beaujon

    Clichy, France

  • Hopital Franco-Britannique - Fondation Cognacq-Jay

    Levallois-Perret, France

  • Clinique de la Sauvegarde

    Lyon, France

  • Centre Hospitalier Universitaire de Montpellier

    Montpellier, France

  • Hopital Saint Antoine

    Paris, France

  • Institut de Cancerologie Gustave Roussy

    Villejuif, France

  • Krebszentrum Reutlingen

    Baden, Germany

  • Krankenhaus Nordwest gGmbH

    Frankfurt, Germany

  • Asklepios Klinik Altona

    Hamburg, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Universitaetsklinikum Heidelberg (UKHD) - Nationales Centrum fuer Tumorerkrankungen Heidelberg (NCT)

    Heidelberg, Germany

  • Ludwig-Maximilians-Universität München Kum

    München, Germany

  • Clinica Oncologica, Ospedali Riuniti Umberto 1

    Ancona, Italy

  • Candiolo Cancer Institute - FPO IRCCS

    Candiolo, Italy

Showing 40 of 87 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.